Compare AUR & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUR | SNN |
|---|---|---|
| Founded | 2017 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 12.3B |
| IPO Year | 2021 | 2002 |
| Metric | AUR | SNN |
|---|---|---|
| Price | $4.91 | $30.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 6 |
| Target Price | $12.13 | ★ $32.32 |
| AVG Volume (30 Days) | ★ 22.2M | 1.1M |
| Earning Date | 10-28-2026 | 08-04-2026 |
| Dividend Yield | N/A | ★ 2.47% |
| EPS Growth | ★ 4.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,000,000.00 | N/A |
| Revenue This Year | $399.72 | $4.89 |
| Revenue Next Year | $1,152.29 | $5.25 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $26.30 |
| 52 Week High | $8.57 | $37.09 |
| Indicator | AUR | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 77.17 |
| Support Level | $4.79 | $29.18 |
| Resistance Level | $5.02 | $31.36 |
| Average True Range (ATR) | 0.29 | 0.47 |
| MACD | -0.04 | 0.43 |
| Stochastic Oscillator | 20.32 | 94.00 |
Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.